| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Michael Scott Salka last filed a Form 4 in April 2017, as Chief Executive Officer at ARMP. Michael Scott Salka's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 11,200 shares of ARMP. Net of sales, the ARMP filings show accumulation of 4,200 shares.
Michael Scott Salka has 4 Form 4 filings on record from August 2015 to April 2017, all as Chief Executive Officer at Armata Pharmaceuticals (ARMP), 2015–2017.
The 4 reported transactions were 2 option or other derivative awards, 1 stock award and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $20K and no sales.
The only open-market purchase was 4,200 shares of ARMP at an average $4.75 on October 5, 2015, about $20K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2015 | ARMP Armata Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 4,200 | $4.75 | $19,950.00 | New |